ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
Is fidaxomicin worth the cost? An economic analysis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review.Infection control and hospital epidemiology · 2018Pooled it
- A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.PharmacoEconomics · 2017Pooled it
- Pooled it
- Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.Antimicrobial agents and chemotherapy · 2018Trial
- Biochemical characterization and X-ray structural and mutagenic analyses of the putative autolysin CdCwlT33800 catalytic domain fromApplied and environmental microbiology · 2025Article
- Clinician Management Preferences forOpen forum infectious diseases · 2025Article
- Loratadine as an Anti-inflammatory Agent Against Clostridium difficile Toxin B.The Journal of infectious diseases · 2024Article
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- ImprovingAntibiotics (Basel, Switzerland) · 2024Article
- Genistein Inhibits Clostridioides difficile Infection via Estrogen Receptors and Lysine-Deficient Protein Kinase 1.The Journal of infectious diseases · 2023Article
- Fidaxomicin to prevent recurrentJAC-antimicrobial resistance · 2023Article
- Is Three Company or a Crowd? Comparing and Contrasting U.S. and EuropeanAntibiotics (Basel, Switzerland) · 2022Review
- Biochemical Characterizations of the Putative Endolysin Ecd09610 Catalytic Domain fromAntibiotics (Basel, Switzerland) · 2022Article
- Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series.Cureus · 2021Article
- Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Article
- Management of Clostridioides difficile infection in patients with inflammatory bowel disease.Intestinal research · 2021Review
- Characterization of an Endolysin TargetingInternational journal of molecular sciences · 2021Article
- Anti-toxin antibody is not associated with recurrent Clostridium difficile infection.Anaerobe · 2021Article
- Navigating changes inJournal of managed care & specialty pharmacy · 2020Review
- Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients.Digestive diseases and sciences · 2020Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundIn May 2011, the Food and Drug Administration approved fidaxomicin for the treatment of Clostridium difficile infection (CDI). It has been found to be noninferior to vancomycin; however, its cost-effectiveness for the treatment of CDI remains undetermined.
methodsWe developed a decision analytic simulation model to determine the economic value of fidaxomicin for CDI treatment from the third-party payer perspective. We looked at CDI treatment in these 3 cases: (1) no fidaxomicin, (2) only fidaxomicin, and (3) fidaxomicin based on strain typing results.
resultsThe incremental cost-effectiveness ratio for fidaxomicin based on screening given current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin was dominated (ie, more costly and less effective) by the other 2 treatment strategies explored. The fidaxomicin strategy tended to remain dominated, even at lower costs. With approximately 50% of CDI due to the NAP1/BI/027 strain, a course of fidaxomicin would need to cost ≤$150 to be cost-effective in the treatment of all CDI cases and between $160 and $400 to be cost-effective for those with a non-NAP1/BI/027 strain (ie, treatment based on strain typing).
conclusionsGiven the current cost and NAP1/BI/027 accounting for approximately 50% of isolates, using fidaxomicin as a first-line treatment for CDI is not cost-effective. However, typing and treatment with fidaxomicin based on strain may be more promising depending on the costs of fidaxomicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.